SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending as investors debate ongoing token dilution and mixed sentiments regarding the exchange's future growth initiatives. Community members are simultaneously buzzing over the native meme coin $MERY.X, highlighting its decentralized structure and perceived security benefits as a key focal point for current market activity.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is attracting intense community debate as the stock faces volatility following a recent share offering priced at $5, with investors divided between those viewing the price dip as a strategic entry point and those expressing frustration over ongoing dilution and management's execution. The conversation is largely centered on the company's ability to scale the Eversense 365 commercial adoption and reach profitability, with participants closely monitoring upcoming earnings and pipeline developments for signs of long-term viability.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt is facing significant downward pressure following its latest earnings report, which highlighted substantial revenue declines and net losses. Despite the bleak financial figures, the community remains divided, with some investors debating the potential of the company's strategic pivot toward AI-driven stablecoin infrastructure and cross-border payment rails.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently trending as investors rotate into high-quality defensive healthcare stocks amid market volatility, while the community remains focused on the company's aggressive oncology pipeline expansion and potential for strategic acquisitions. Investors are actively discussing the company's ongoing litigation risks alongside its long-term growth prospects as a potential sector leader in cancer treatment.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors digest a strong quarterly earnings report featuring revenue that exceeded expectations and raised full-year guidance, even as the stock faces ongoing pressure from heavy short interest. Community discussion is sharply divided between long-term bulls highlighting institutional support and progress in FAA certification, and skeptics focused on cash burn and the company's long-term path to commercial profitability.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending as investors weigh significant long-term growth potential in its ophthalmology portfolio against recent volatility caused by management guidance adjustments and institutional selling. While community sentiment remains largely bullish, focusing on the rapid adoption of Vevye and upcoming biosimilar launches, investors are actively debating the timing of revenue execution and the company's ability to consistently meet future financial targets.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is seeing a surge in community engagement as investors track the CEO's involvement in high-level government roundtables on critical minerals and the company's role as a sole domestic supplier for defense applications. While community discourse remains heavily focused on potential supply chain catalysts, institutional activity, and the upcoming earnings report, sentiment is polarized between long-term holders eyeing strategic supply shortages and those concerned by recent volatility.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance is surging as the company reports record revenue and gross margins, signaling a transition into a scalable, multi-indication growth stock that is far exceeding analyst expectations. Community sentiment is overwhelmingly bullish, with investors actively discussing potential short squeezes and long-term rerating driven by robust demand and highly anticipated upcoming pipeline data for non-small cell lung cancer.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to FDA regulatory milestones and an expanding oncology pipeline, with the community actively debating the company's long-term commercialization strategy versus potential short-term volatility. Traders are closely monitoring heavy short interest and institutional accumulation, fueling speculation about a sustained squeeze as the stock reaches new highs.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is experiencing significant volatility and trading volume as investors react to mixed economic signals, including elevated inflation data and ongoing central bank gold accumulation. The community remains divided, with many debating whether the current pullback represents a strategic bottoming phase or a deeper correction driven by interest rate uncertainties and broader market instability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
